TREVI THERAPEUTICS INC (TRVI) Stock Overview
USA - NASDAQ:TRVI - US89532M1018 - Common Stock
TRVI Key Statistics, Chart & Performance
The current stock price of TRVI is 10.51 USD. In the past month the price increased by 19.84%. In the past year, price increased by 236.86%.
TRVI Latest News, Press Relases and Analysis
TRVI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 51.11 | 781.26B | ||
| JNJ | JOHNSON & JOHNSON | 18.34 | 458.55B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.76 | 258.24B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.73 | 252.36B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 13.65 | 235.32B | ||
| MRK | MERCK & CO. INC. | 11.36 | 218.53B | ||
| PFE | PFIZER INC | 7.3 | 140.77B | ||
| SNY | SANOFI-ADR | 11.74 | 125.85B | ||
| GSK | GSK PLC-SPON ADR | 9.65 | 86.97B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.51 | 89.21B | ||
| ZTS | ZOETIS INC | 23.46 | 64.68B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 50.04 | 44.25B |
Related stock screener links
About TRVI
Company Profile
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is headquartered in New Haven, Connecticut and currently employs 26 full-time employees. The company went IPO on 2019-05-07. The firm is focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), chronic cough in patients with non-IPF interstitial lung disease, and refractory chronic cough. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed kappa-opioid receptor agonist and mu-opioid receptor antagonist. The company has conducted a Phase II clinical trial and an open-label extension study of Haduvio in pruritus in patients with prurigo nodularis and a Phase IIb/III clinical trial. The Company’s Haduvio development programs include Chronic Cough in IPF Program, RCC Program, and Prurigo Nodularis Program. The Company’s subsidiary is Trevi Therapeutics Limited.
Company Info
TREVI THERAPEUTICS INC
195 Church Street, 16Th Floor
New Haven CONNECTICUT 06510 US
CEO: Jennifer Good
Employees: 26
Phone: 12033042499
TREVI THERAPEUTICS INC / TRVI FAQ
Can you describe the business of TREVI THERAPEUTICS INC?
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is headquartered in New Haven, Connecticut and currently employs 26 full-time employees. The company went IPO on 2019-05-07. The firm is focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), chronic cough in patients with non-IPF interstitial lung disease, and refractory chronic cough. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed kappa-opioid receptor agonist and mu-opioid receptor antagonist. The company has conducted a Phase II clinical trial and an open-label extension study of Haduvio in pruritus in patients with prurigo nodularis and a Phase IIb/III clinical trial. The Company’s Haduvio development programs include Chronic Cough in IPF Program, RCC Program, and Prurigo Nodularis Program. The Company’s subsidiary is Trevi Therapeutics Limited.
What is the stock price of TREVI THERAPEUTICS INC today?
The current stock price of TRVI is 10.51 USD. The price decreased by -1.31% in the last trading session.
What is the dividend status of TREVI THERAPEUTICS INC?
TRVI does not pay a dividend.
How is the ChartMill rating for TREVI THERAPEUTICS INC?
TRVI has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Which stock exchange lists TRVI stock?
TRVI stock is listed on the Nasdaq exchange.
What is TREVI THERAPEUTICS INC worth?
TREVI THERAPEUTICS INC (TRVI) has a market capitalization of 1.28B USD. This makes TRVI a Small Cap stock.
When does TREVI THERAPEUTICS INC (TRVI) report earnings?
TREVI THERAPEUTICS INC (TRVI) will report earnings on 2025-11-05.
TRVI Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to TRVI. When comparing the yearly performance of all stocks, TRVI is one of the better performing stocks in the market, outperforming 97.39% of all stocks.
TRVI Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to TRVI. No worries on liquidiy or solvency for TRVI as it has an excellent financial health rating, but there are worries on the profitability.
TRVI Financial Highlights
Over the last trailing twelve months TRVI reported a non-GAAP Earnings per Share(EPS) of -0.42. The EPS decreased by -7.69% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -22.12% | ||
| ROE | -23.23% | ||
| Debt/Equity | 0 |
TRVI Forecast & Estimates
18 analysts have analysed TRVI and the average price target is 19.98 USD. This implies a price increase of 90.06% is expected in the next year compared to the current price of 10.51.